Floatz logo

ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)

Unresectable Ureter Urothelial Carcinoma

Fred Hutchinson Cancer Centerantibody_drug_conjugatePhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

5 Active assets in the Unresectable Ureter Urothelial Carcinoma cohort.

Asset / SponsorPhaseRating
Pembrolizumab
Fred Hutchinson Cancer Center
Phase 2B
Epirubicin
Fred Hutchinson Cancer Center
Phase 2B
Cyclophosphamide
Fred Hutchinson Cancer Center
Phase 2B
Atezolizumab
National Cancer Institute (NCI)
Phase 2B
ERIBULIN MONOMETHANESULFONATE
National Cancer Institute (NCI)
Phase 2CCC
Fludarabine
Roswell Park Cancer Institute
Phase 2CCC
Lifileucel
Roswell Park Cancer Institute
Phase 2CCC

Same molecule, other indications

ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4) is also rated in:

urothelial carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
urinary bladder neoplasmDormant
BB
Indicative ·
68 / 100
View asset →
ureter neoplasmDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →